![Metronomic chemotherapy of thalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients - Clinical Lymphoma, Myeloma and Leukemia Metronomic chemotherapy of thalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients - Clinical Lymphoma, Myeloma and Leukemia](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2037463118/2051918849/fx1.jpg)
Metronomic chemotherapy of thalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients - Clinical Lymphoma, Myeloma and Leukemia
![Metronomic cyclophosphamide and methotrexate for breast cancer: Enhanced efficacy by adding dalteparin and low-dose prednisone? - The Breast Metronomic cyclophosphamide and methotrexate for breast cancer: Enhanced efficacy by adding dalteparin and low-dose prednisone? - The Breast](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/cadf9b5b-0a36-43a6-b3ce-e054987c2837/gr1_lrg.jpg)
Metronomic cyclophosphamide and methotrexate for breast cancer: Enhanced efficacy by adding dalteparin and low-dose prednisone? - The Breast
![Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts | Oncogene Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts | Oncogene](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsj.onc.1211031/MediaObjects/41388_2008_Article_BF1211031_Fig1_HTML.gif)
Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts | Oncogene
![Oral Metronomic Cyclophosphamide with and without Methotrexate as Palliative Treatment for Patients with Metastatic Breast Carcinoma | Anticancer Research Oral Metronomic Cyclophosphamide with and without Methotrexate as Palliative Treatment for Patients with Metastatic Breast Carcinoma | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/32/2/529/F1.large.jpg)
Oral Metronomic Cyclophosphamide with and without Methotrexate as Palliative Treatment for Patients with Metastatic Breast Carcinoma | Anticancer Research
![Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer | npj Breast Cancer Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer | npj Breast Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41523-020-0171-1/MediaObjects/41523_2020_171_Fig2_HTML.png)
Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer | npj Breast Cancer
![Metronomic cyclophosphamide: An alternative treatment for hepatic epithelioid hemangioendothelioma - Journal of Hepatology Metronomic cyclophosphamide: An alternative treatment for hepatic epithelioid hemangioendothelioma - Journal of Hepatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2007828112/2029969809/gr1.jpg)
Metronomic cyclophosphamide: An alternative treatment for hepatic epithelioid hemangioendothelioma - Journal of Hepatology
![Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity - Annals of Oncology Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b7709404-316f-4f7a-8259-42068626b5e3/gr1.jpg)
Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity - Annals of Oncology
![Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM) - Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM) -](https://ars.els-cdn.com/content/image/1-s2.0-S0960977620301223-gr1.jpg)
Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM) -
![A Dose-finding Study of Metronomic Oral Vinorelbine in Combination With Oral Cyclophosphamide and Bevacizumab in Patients With Advanced Breast Cancer - Clinical Breast Cancer A Dose-finding Study of Metronomic Oral Vinorelbine in Combination With Oral Cyclophosphamide and Bevacizumab in Patients With Advanced Breast Cancer - Clinical Breast Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/4409ff73-748d-4dc1-9fe5-862e3713859a/gr1.jpg)
A Dose-finding Study of Metronomic Oral Vinorelbine in Combination With Oral Cyclophosphamide and Bevacizumab in Patients With Advanced Breast Cancer - Clinical Breast Cancer
![Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts | Oncogene Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts | Oncogene](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fsj.onc.1211031/MediaObjects/41388_2008_Article_BF1211031_Fig2_HTML.jpg)
Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts | Oncogene
![Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers | EMBO Molecular Medicine Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers | EMBO Molecular Medicine](https://www.embopress.org/cms/asset/1ce4bc06-596b-44bb-ab79-cd6b8c81bca6/emmm201911416-abs-0001-m.jpg)
Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers | EMBO Molecular Medicine
![A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer - Gynecologic Oncology A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer - Gynecologic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/34fefc2f-117c-4c56-b99c-2cbacd9cec73/gr1_lrg.jpg)
A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer - Gynecologic Oncology
Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T... | Oncotarget
![Effects of sunitinib, lenalidomide, and metronomic cyclophosphamide on... | Download Scientific Diagram Effects of sunitinib, lenalidomide, and metronomic cyclophosphamide on... | Download Scientific Diagram](https://www.researchgate.net/profile/Steven-Libutti-2/publication/5678084/figure/fig3/AS:667849332903948@1536239097404/Effects-of-sunitinib-lenalidomide-and-metronomic-cyclophosphamide-on-endothelial-cell.png)
Effects of sunitinib, lenalidomide, and metronomic cyclophosphamide on... | Download Scientific Diagram
![Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study | BMC Cancer | Full Text Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F1471-2407-14-947/MediaObjects/12885_2014_Article_5119_Fig2_HTML.jpg)
Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study | BMC Cancer | Full Text
![Metronomic oral cyclophosphamide in relapsed ovarian cancer | International Journal of Gynecologic Cancer Metronomic oral cyclophosphamide in relapsed ovarian cancer | International Journal of Gynecologic Cancer](https://ijgc.bmj.com/content/ijgc/31/7/1037/F1.large.jpg)
Metronomic oral cyclophosphamide in relapsed ovarian cancer | International Journal of Gynecologic Cancer
![A) Antitumor activity of metronomic cyclophosphamide, single low-dose... | Download Scientific Diagram A) Antitumor activity of metronomic cyclophosphamide, single low-dose... | Download Scientific Diagram](https://www.researchgate.net/profile/Jorge-B-Aquino/publication/233739113/figure/fig1/AS:202905626910720@1425387879032/Figure1-A-Antitumor-activity-of-metronomic-cyclophosphamide-single-low-dose.png)
A) Antitumor activity of metronomic cyclophosphamide, single low-dose... | Download Scientific Diagram
![Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer | npj Breast Cancer Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer | npj Breast Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41523-020-0171-1/MediaObjects/41523_2020_171_Fig3_HTML.png)
Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer | npj Breast Cancer
![Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center - Lu - 2020 - Cancer Communications - Wiley Online Library Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center - Lu - 2020 - Cancer Communications - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/346166b6-47b0-47bf-bcb3-9ebcd9e82914/cac2.v40.5.cover.jpg)